Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab - PubMed (original) (raw)
Review
Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab
William Tausend et al. J Cutan Med Surg. 2014 May-Jun.
Abstract
Background: Monoclonal antibodies known as biologic agents specifically targeted against interleukin-12 (IL-12), interleukin-17A (IL-17), and interleukin-23 (IL-23) have been the focus of research for moderate-to-severe chronic plaque psoriasis in recent years.
Objectives: To discuss the immune-mediated model of psoriasis and to summarize current knowledge of the clinical efficacy and safety of new biologic agents for moderate-to-severe chronic plaque psoriasis.
Methods: The PubMed database was searched for relevant articles on ustekinumab, briakinumab, tildrakizumab (MK-322), guselkumab, secukinumab, ixekizumab, and brodalumab published between January 2005 and July 2013.
Results: Fifty-five articles were identified. These studies suggest that the biologic agents specifically targeting IL-12, IL-17, and IL-23 are efficacious and safe in the treatment of moderate-to-severe psoriasis in adults.
Conclusion: Current data from clinical trials suggest that biologic agents targeting IL-12, IL-17, and IL-23 are safe and efficacious drugs for use in moderate-to-severe chronic plaque psoriasis. Long-term data still need to be established.
Similar articles
- A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB. Bilal J, et al. J Dermatolog Treat. 2018 Sep;29(6):569-578. doi: 10.1080/09546634.2017.1422591. Epub 2018 Mar 28. J Dermatolog Treat. 2018. PMID: 29532693 Review. - Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
Jeon C, Sekhon S, Yan D, Afifi L, Nakamura M, Bhutani T. Jeon C, et al. Hum Vaccin Immunother. 2017 Oct 3;13(10):2247-2259. doi: 10.1080/21645515.2017.1356498. Hum Vaccin Immunother. 2017. PMID: 28825875 Free PMC article. Review. - Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Bai F, Li GG, Liu Q, Niu X, Li R, Ma H. Bai F, et al. J Immunol Res. 2019 Sep 10;2019:2546161. doi: 10.1155/2019/2546161. eCollection 2019. J Immunol Res. 2019. PMID: 31583255 Free PMC article. - New and emerging therapies in psoriasis.
Leonardi CL, Gordon KB. Leonardi CL, et al. Semin Cutan Med Surg. 2014 Mar;33(2 Suppl 2):S37-41. doi: 10.12788/j.sder.0066. Semin Cutan Med Surg. 2014. PMID: 24979544 - Biologics for Psoriasis.
Wride AM, Chen GF, Spaulding SL, Tkachenko E, Cohen JM. Wride AM, et al. Dermatol Clin. 2024 Jul;42(3):339-355. doi: 10.1016/j.det.2024.02.001. Epub 2024 Mar 13. Dermatol Clin. 2024. PMID: 38796266 Review.
Cited by
- PepFect14 mediates the delivery of mRNA into human primary keratinocytes and in vivo.
Periyasamy K, Maloverjan M, Biswas A, Remm A, Pook M, Rebane A, Pooga M. Periyasamy K, et al. Front Pharmacol. 2023 Jul 13;14:1219761. doi: 10.3389/fphar.2023.1219761. eCollection 2023. Front Pharmacol. 2023. PMID: 37521463 Free PMC article. - Plaque psoriasis and morphea in a patient on ustekinumab: A case report.
Cirone K, Vender R. Cirone K, et al. SAGE Open Med Case Rep. 2023 Mar 29;11:2050313X231164207. doi: 10.1177/2050313X231164207. eCollection 2023. SAGE Open Med Case Rep. 2023. PMID: 37009548 Free PMC article. - A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab.
Ghazawi FM, Mahmood F, Kircik L, Poulin Y, Bourcier M, Vender R, Wiseman MC, Lynde C, Litvinov IV. Ghazawi FM, et al. Front Med (Lausanne). 2021 Aug 10;8:702776. doi: 10.3389/fmed.2021.702776. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34447766 Free PMC article. Review. - Psoriasis and Cardiovascular Disease: A Narrative Review.
Martinez-Moreno A, Ocampo-Candiani J, Garza-Rodriguez V. Martinez-Moreno A, et al. Korean J Fam Med. 2021 Sep;42(5):345-355. doi: 10.4082/kjfm.20.0053. Epub 2020 Jun 9. Korean J Fam Med. 2021. PMID: 32512983 Free PMC article. - Chronic maternal interleukin-17 and autism-related cortical gene expression, neurobiology, and behavior.
Gumusoglu SB, Hing BWQ, Chilukuri ASS, Dewitt JJ, Scroggins SM, Stevens HE. Gumusoglu SB, et al. Neuropsychopharmacology. 2020 May;45(6):1008-1017. doi: 10.1038/s41386-020-0640-0. Epub 2020 Feb 19. Neuropsychopharmacology. 2020. PMID: 32074626 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical